Literature DB >> 15922317

Studies toward a conjugate vaccine for anthrax. Synthesis and characterization of anthrose [4,6-dideoxy-4-(3-hydroxy-3-methylbutanamido)-2-O-methyl-D-glucopyranose] and its methyl glycosides.

Rina Saksena1, Roberto Adamo, Pavol Kovác.   

Abstract

The key step in the first chemical synthesis of anthrose (16) and its methyl alpha- (6) and beta-glycoside (22) was inversion of configuration at C-2 in triflates 10, 2, and 18, respectively, obtained from the common intermediate, methyl 4-azido-3-O-benzyl-4,6-dideoxy-alpha-D-mannopyranoside (1). To prepare methyl alpha-anthroside (6), methylation at O-2 of the gluco product 3, obtained from 2, was followed by hydrogenation/hydrogenolysis of the formed 2-methyl ether 4, to simultaneously remove the protecting benzyl group and reduce the azido function. Subsequent N-acylation of the formed amine 5 with 3-hydroxy-3-methylbutyric acid gave the target methyl alpha-glycoside 6. Synthesis of methyl beta-anthroside (22) comprised the same sequence of reactions, starting from the known methyl 4-azido-3-O-benzyl-4,6-dideoxy-beta-D-mannopyranoside (17), which was prepared from 1. In the synthesis of anthrose (16), 1-thio-beta-glucoside 11, obtained from 1 through 10, was methylated at O-2, and the azido function in the resulting benzylated 1-thioglycoside 12 was selectively reduced to give amine 13. After N-acylation with 3-hydroxy-3-methylbutyric acid, 1-thioglycoside 14 was hydrolyzed to give the corresponding reducing sugar, aldol 15, which was debenzylated to afford anthrose.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15922317     DOI: 10.1016/j.carres.2005.04.010

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  8 in total

1.  Identification of an African Bacillus anthracis lineage that lacks expression of the spore surface-associated anthrose-containing oligosaccharide.

Authors:  Marco Tamborrini; Mark Bauer; Miriam Bolz; Angaya Maho; Matthias A Oberli; Daniel B Werz; Esther Schelling; Jakob Zinsstag; Peter H Seeberger; Joachim Frey; Gerd Pluschke
Journal:  J Bacteriol       Date:  2011-05-13       Impact factor: 3.490

2.  Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery.

Authors:  Denong Wang
Journal:  J Proteomics Bioinform       Date:  2014-02-25

3.  Anthrax spore detection by a luminex assay based on monoclonal antibodies that recognize anthrose-containing oligosaccharides.

Authors:  Marco Tamborrini; Marcelle Holzer; Peter H Seeberger; Nadia Schürch; Gerd Pluschke
Journal:  Clin Vaccine Immunol       Date:  2010-07-21

4.  Saccharides cross-reactive with Bacillus anthracis spore glycoprotein as an anthrax vaccine component.

Authors:  Joanna Kubler-Kielb; Evgeny Vinogradov; Haijing Hu; Stephen H Leppla; John B Robbins; Rachel Schneerson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

5.  Multimeric bivalent immunogens from recombinant tetanus toxin HC fragment, synthetic hexasaccharides, and a glycopeptide adjuvant.

Authors:  Aileen F G Bongat; Rina Saksena; Roberto Adamo; Yukari Fujimoto; Zenyu Shiokawa; Dwight C Peterson; Koichi Fukase; Willie F Vann; Pavol Kovác
Journal:  Glycoconj J       Date:  2009-09-16       Impact factor: 2.916

6.  Synthesis of the antigenic tetrasaccharide side chain from the major glycoprotein of Bacillus anthracis exosporium.

Authors:  David Crich; Olga Vinogradova
Journal:  J Org Chem       Date:  2007-07-28       Impact factor: 4.354

7.  Immunogens related to the synthetic tetrasaccharide side chain of the Bacillus anthracis exosporium.

Authors:  Rina Saksena; Roberto Adamo; Pavol Kovác
Journal:  Bioorg Med Chem       Date:  2007-03-23       Impact factor: 3.641

8.  Structure-Immunogenicity Relationship of α- and β-Tetrasaccharide Glycoforms from Bacillus anthracis Exosporium and Fragments Thereof.

Authors:  Riccardo De Ricco; Christy L Ventura; Filippo Carboni; Rina Saksena; Pavol Kováč; Roberto Adamo
Journal:  Molecules       Date:  2018-08-20       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.